Intuitive Surgical Expands Direct Reach: Plans Acquiring Key European da Vinci And Ion Distribution Businesses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2025
0mins
Should l Buy ISRG?
Source: Benzinga
Acquisition Announcement: Intuitive Surgical, Inc. plans to acquire the da Vinci and Ion distribution businesses in Italy, Spain, Portugal, Malta, San Marino, and associated territories, with the deal expected to close in 2026 pending regulatory approvals.
Strategic Importance: CEO Gary Guthart highlighted the significance of having a direct presence in these regions to better understand customer needs and enhance access to minimally invasive care across Europe.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 458.080
Low
575.00
Averages
637.32
High
740.00
Current: 458.080
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aging Population Boosts Intuitive Surgical's Growth Potential
- Market Share Advantage: Intuitive Surgical's da Vinci robotic surgery system commands nearly 60% market share, and as the first mover in the field, its widespread use in surgical training solidifies its competitive edge and drives ongoing growth.
- Aging Population Driver: By 2030, the senior population in the U.S. is projected to reach 73 million, and with increasing surgical demand, Intuitive Surgical stands to benefit significantly from this 'silver tsunami' trend, further propelling revenue growth and market share expansion.
- International Market Expansion: Intuitive Surgical is working to increase its penetration in overseas markets, where its da Vinci system currently has low market presence, and future market expansion will provide new growth opportunities for the company.
- Profitability and Valuation: Although shares currently trade at 45 times forward earnings, higher than many other medical device companies, if the company continues to grow at a double-digit pace, its stock is likely to maintain a premium valuation, reflecting market recognition of its growth potential.
See More
Jim Cramer Updates Bullpen Watchlist with New Stocks
- New Additions: Jim Cramer added ARM Holdings and FedEx to the Bullpen, with ARM's recent in-house chip launch making it a bullish prospect at $161 per share, while FedEx, up about 30% this year, remains 'dramatically undervalued'.
- FedEx Restructuring: FedEx is spinning off its less-than-truckload unit, FedEx Freight, expected to complete by June 1, a move that typically creates more shareholder value, with Jim praising CEO Raj Subramaniam for navigating a competitive landscape effectively.
- Removed Stocks: Jim removed Airbnb and Marvell Technology from the watchlist, citing Airbnb's episodic performance as a concern, while Marvell's 57% rally in 2026 indicated a missed buying opportunity.
- Market Monitoring: Jim continues to monitor Sempra and RTX Corporation, with Sempra up over 8% year-to-date, while RTX could benefit from increased defense production, with Jim planning to decide post RTX's first-quarter results on April 21.
See More
Structural Shift in U.S. Heart Care Market
- Market Growth Potential: The U.S. cardiovascular devices market is projected to grow from $22.08 billion in 2025 to $41.29 billion by 2032, reflecting a nearly 11.3% annual growth rate, indicating significant demand driven by an aging population.
- AI Tool Adoption: Currently, 75% of U.S. health systems are rolling out AI-powered clinical tools, particularly in cardiac imaging and documentation, which will create asymmetric growth opportunities for companies in this sector.
- New Partnership: VentriPoint Diagnostics has secured a new partnership with the Montecristo Group to deploy its AI cardiac imaging platform across Costa Rica, which is expected to enhance the efficiency and accuracy of cardiac disease screening in the region, further expanding market share.
- Technological Advantage: VentriPoint's VMS+™ system converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRIs at a significantly lower cost, which is anticipated to drive the widespread adoption of cardiac diagnostics.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Costco, Intuitive Surgical, and Visa Show Strong Growth Potential
- Costco's Investment Returns: Over the past decade, Costco's stock has generated total returns exceeding 671%, significantly outpacing the S&P 500's 281%, indicating that a $10,000 investment in 2016 has grown to over $77,100, showcasing its strong performance in the consumer staples sector.
- Intuitive Surgical's Market Potential: Intuitive Surgical's da Vinci robotic surgery systems support over 3 million surgeries annually, and despite facing short-term challenges like cybersecurity incidents, the company's market penetration remains low, suggesting substantial growth potential with expected returns of over 250% in the next decade.
- Visa's Growth Trend: Since 2016, Visa's stock has delivered total returns of 316%, slightly above the S&P 500, but its core position in the global digital payment trend remains strong, particularly in underpenetrated markets like Africa and Latin America.
- Attractive Dividend Growth: Both Costco and Visa exhibit impressive dividend growth, with Costco averaging nearly 13% annual dividend growth over the past five years, while Visa has raised its dividend for 18 consecutive years, averaging nearly 15% growth, providing investors with a stable return source.
See More
Three Stocks Expected to Outperform the Market
- Costco's Strong Returns: Over the past decade, Costco's stock has generated total returns exceeding 671%, significantly outpacing the S&P 500's 281%, indicating that its competitive advantage in consumer staples will continue to drive stock price growth.
- Intuitive Surgical's Market Potential: Intuitive Surgical's da Vinci systems support over 3 million surgeries annually, and despite facing short-term pressures from cybersecurity incidents, its market penetration still has substantial room for growth, with expected annual earnings growth of 12% to 14% over the next decade.
- Visa's Digital Payment Trend: Visa has generated total returns of 316% since 2016, and while concerns about stablecoin competition exist, the ongoing trend of digital payment adoption globally, especially in emerging markets like Africa and Latin America, is expected to provide long-term growth opportunities.
- Dividend Growth Stability: Both Costco and Visa exhibit strong dividend growth, with Costco averaging nearly 13% annual growth over the past five years, while Visa has raised its dividend for 18 consecutive years with an average growth rate of nearly 15%, further enhancing investor confidence.
See More
Aging Population Boosts Intuitive Surgical's Growth Potential
- Market Share Advantage: Intuitive Surgical's da Vinci robotic surgery system commands nearly 60% market share, and as the first mover in the field, its widespread use in surgical training solidifies its competitive edge and drives ongoing growth.
- Aging Population Driver: By 2030, the senior population in the U.S. is projected to reach 73 million, and with increasing surgical demand, Intuitive Surgical stands to benefit significantly from this 'silver tsunami' trend, further propelling revenue growth and market share expansion.
- International Market Expansion: Intuitive Surgical is working to increase its penetration in overseas markets, where its da Vinci system currently has low market presence, and future market expansion will provide new growth opportunities for the company.
- Profitability and Valuation: Although shares currently trade at 45 times forward earnings, higher than many other medical device companies, if the company continues to grow at a double-digit pace, its stock is likely to maintain a premium valuation, reflecting market recognition of its growth potential.
See More
Jim Cramer Updates Bullpen Watchlist with New Stocks
- New Additions: Jim Cramer added ARM Holdings and FedEx to the Bullpen, with ARM's recent in-house chip launch making it a bullish prospect at $161 per share, while FedEx, up about 30% this year, remains 'dramatically undervalued'.
- FedEx Restructuring: FedEx is spinning off its less-than-truckload unit, FedEx Freight, expected to complete by June 1, a move that typically creates more shareholder value, with Jim praising CEO Raj Subramaniam for navigating a competitive landscape effectively.
- Removed Stocks: Jim removed Airbnb and Marvell Technology from the watchlist, citing Airbnb's episodic performance as a concern, while Marvell's 57% rally in 2026 indicated a missed buying opportunity.
- Market Monitoring: Jim continues to monitor Sempra and RTX Corporation, with Sempra up over 8% year-to-date, while RTX could benefit from increased defense production, with Jim planning to decide post RTX's first-quarter results on April 21.
See More
Structural Shift in U.S. Heart Care Market
- Market Growth Potential: The U.S. cardiovascular devices market is projected to grow from $22.08 billion in 2025 to $41.29 billion by 2032, reflecting a nearly 11.3% annual growth rate, indicating significant demand driven by an aging population.
- AI Tool Adoption: Currently, 75% of U.S. health systems are rolling out AI-powered clinical tools, particularly in cardiac imaging and documentation, which will create asymmetric growth opportunities for companies in this sector.
- New Partnership: VentriPoint Diagnostics has secured a new partnership with the Montecristo Group to deploy its AI cardiac imaging platform across Costa Rica, which is expected to enhance the efficiency and accuracy of cardiac disease screening in the region, further expanding market share.
- Technological Advantage: VentriPoint's VMS+™ system converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRIs at a significantly lower cost, which is anticipated to drive the widespread adoption of cardiac diagnostics.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Costco, Intuitive Surgical, and Visa Show Strong Growth Potential
- Costco's Investment Returns: Over the past decade, Costco's stock has generated total returns exceeding 671%, significantly outpacing the S&P 500's 281%, indicating that a $10,000 investment in 2016 has grown to over $77,100, showcasing its strong performance in the consumer staples sector.
- Intuitive Surgical's Market Potential: Intuitive Surgical's da Vinci robotic surgery systems support over 3 million surgeries annually, and despite facing short-term challenges like cybersecurity incidents, the company's market penetration remains low, suggesting substantial growth potential with expected returns of over 250% in the next decade.
- Visa's Growth Trend: Since 2016, Visa's stock has delivered total returns of 316%, slightly above the S&P 500, but its core position in the global digital payment trend remains strong, particularly in underpenetrated markets like Africa and Latin America.
- Attractive Dividend Growth: Both Costco and Visa exhibit impressive dividend growth, with Costco averaging nearly 13% annual dividend growth over the past five years, while Visa has raised its dividend for 18 consecutive years, averaging nearly 15% growth, providing investors with a stable return source.
See More
Three Stocks Expected to Outperform the Market
- Costco's Strong Returns: Over the past decade, Costco's stock has generated total returns exceeding 671%, significantly outpacing the S&P 500's 281%, indicating that its competitive advantage in consumer staples will continue to drive stock price growth.
- Intuitive Surgical's Market Potential: Intuitive Surgical's da Vinci systems support over 3 million surgeries annually, and despite facing short-term pressures from cybersecurity incidents, its market penetration still has substantial room for growth, with expected annual earnings growth of 12% to 14% over the next decade.
- Visa's Digital Payment Trend: Visa has generated total returns of 316% since 2016, and while concerns about stablecoin competition exist, the ongoing trend of digital payment adoption globally, especially in emerging markets like Africa and Latin America, is expected to provide long-term growth opportunities.
- Dividend Growth Stability: Both Costco and Visa exhibit strong dividend growth, with Costco averaging nearly 13% annual growth over the past five years, while Visa has raised its dividend for 18 consecutive years with an average growth rate of nearly 15%, further enhancing investor confidence.
See More
